Barclays’s Sonnet BioTherapeutics SONN Stock Holding History

Barclays’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-17	Closed	-$23	–	5521
2025 Q1	$23	Buy	+17	New	+$26	﹤0.01%	5167
2017 Q1	–	Hold	0	–	-$1K	–	6958
2016 Q4	–	Hold	0	–	–	–	6490
2016 Q3	–	Hold	0	–	–	–	6271
2016 Q2	–	Hold	0	–	–	–	5982

Other funds holding SONN

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CWA

Carolina Wealth Advisors Myrtle Beach, South Carolina $255M AUM 17.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Barclays's SONN Position: Q2 2025 in Review

Barclays sold out of Sonnet BioTherapeutics (SONN) in Q2 2025, closing a stake of 17 shares — an estimated $23 sold.

Barclays first reported a position in SONN in Q1 2025 and held it in 1 quarter. The position peaked at $23 in Q1 2025. 9 funds tracked by Wall St. Rank hold SONN as of Q2 2025.

Barclays reported no remaining Sonnet BioTherapeutics position as of Q2 2025 after selling out during the quarter.
Barclays sold 17 Sonnet BioTherapeutics shares in Q2 2025, an estimated $23.
Barclays first reported a position in Sonnet BioTherapeutics in Q1 2025 and held it in 1 quarter.
Barclays's Sonnet BioTherapeutics position peaked at $23 in Q1 2025.
9 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.